These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23930754)

  • 1. Targeted therapy for NSCLC with driver mutations.
    Minuti G; D'Incecco A; Cappuzzo F
    Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
    Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
    Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging protein kinase inhibitors for non-small cell lung cancer.
    Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in nonsmall cell lung cancer.
    Puri T
    Indian J Cancer; 2017; 54(1):83-88. PubMed ID: 29199670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
    Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
    Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare mutations in non-small-cell lung cancer.
    D'Arcangelo M; D'Incecco A; Cappuzzo F
    Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging targeted therapies in non-small cell lung cancer.
    Khanal N; Ganti AK
    Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
    Reungwetwattana T; Weroha SJ; Molina JR
    Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.
    Cheng L; Zhang S; Alexander R; Yao Y; MacLennan GT; Pan CX; Huang J; Wang M; Montironi R; Lopez-Beltran A
    Future Oncol; 2011 Apr; 7(4):519-41. PubMed ID: 21463141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M; Wynes MW; Hirsch FR
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Targets in Non-Small Cell Lung Cancer.
    Park SJ; More S; Murtuza A; Woodward BD; Husain H
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):113-129. PubMed ID: 27912827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
    Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
    Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
    Rossi G; Graziano P; Leone A; Migaldi M; Califano R
    Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular profiling of non-small cell lung cancer].
    Gibault L; Cazes A; Narjoz C; Blons H
    Rev Pneumol Clin; 2014; 70(1-2):47-62. PubMed ID: 24566035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line therapy of mutated non-small cell lung cancer: an update.
    Stöhlmacher-Williams J
    Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    Tan AC; Tan DSW
    J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.